The February 2026 EDE multi-agent mechanism and contract restructuring

1. Key takeaways

On 24 February 2026, EDE activated, under Federal Decree-Law No. 38/2024, the mechanism that breaks monopolies over medical products, requiring companies to designate more than 1 authorised agent for every medical product marketed in the UAE. This is not a declaratory statement; it is the move that pushes the quantitative requirements of Article 22 from paper into enforcement. What Chinese manufacturers must redo is not merely contract wording: wherever the original licensing, import, distribution and vigilance links were carried by a single partner, the whole architecture, together with the supply chain, the pricing system and the allocation of responsibility, needs to be redesigned.

• Every medical product marketed in the UAE must now have more than 1 authorised agent.
• Compliance turns on whether agency relationships are objectively established and provable, not on signed letters of intent.
• Multiple parallel agents compress rebate margins once landed costs are compared horizontally.
• Standardised document templates and traceability coding must be issued uniformly to all agents.

2. Legal basis

The table below pairs the February 2026 announcement with the decree provisions it operationalises, including the import prohibition that applies absent a marketing authorisation.

3. Expert insights

Insight 1: what this mechanism tests is the act of designation, not the redistribution of stock. The announcement turns on the requirement that every product have more than 1 authorised agent, and compliance verification looks at whether the agency relationships have been objectively established and can be evidenced. Our judgement is that companies tend to reduce this to signing one more letter of intent, whereas the substantive requirement is enforceable contractual relationships and the actual performance capability of the corresponding entities. The test should return to Article 22(2)-(4): can the company produce this agent’s genuine import and supply records for the current year?

Insight 2: what the new mechanism recovers is pricing and supply flexibility, and Chinese manufacturers should respond proactively. Under a single-agent structure, terminal prices, supply rhythm and market investment are highly concentrated in one hand. Once multiple agents operate in parallel, horizontal price comparison emerges between agents and the quotation system comes under pressure. Customs duty levied at 5% of the CIF value (practical estimate) is itself unaffected by the mechanism, but once landed costs are compared across agents, the rebate margin is compressed. We recommend unifying, in advance within the commercial policy, the ex-works price, the tiered rebate scheme and the handling of cross-territory sales; otherwise the price system typically falls into disorder in the first procurement season after the second agent enters.

Insight 3: supply chain arrangements must be redone in step, otherwise the contracts change and the goods still do not come in. Multiple agents mean multiple customs declaration flows, multiple document template sets and multiple ports of arrival. The official time limits of 3 working days for the initial import permit and 2 working days for clearance on arrival hold only where the documents are complete. Our recommendation is to turn document templates, traceability coding rules and the vigilance information return path into standardised deliverables, issued uniformly to all agents, compressing the pattern of one practice per agent into one practice executed by many.

4. Practical recommendations

• Inventory the number of authorised agents for every existing medical product, confirm one by one whether each product has more than 1, and close gaps product by product.
• Redo the agency contract template: delete exclusive import or exclusive distribution clauses, and define each agent’s territory, channel, annual minimum import obligation and liability for breach.
• Unify the commercial policy document, defining the ex-works price, rebate rules and the handling of cross-territory sales, to prevent price disorder once multiple agents operate in parallel.
• Establish a standardised document package and traceability coding rules, issued uniformly to all agents with records kept, reducing clearance delays caused by inconsistent documents.
• Set a qualification-check node for new agents, verifying their EDE licence type and scope of activities before commercial terms are signed.
• Write agent changes, certificate handover and stock buy-back into the termination clauses, avoiding a licensing or supply vacuum during the switch.

5. Verification checklist

• □ The number of authorised agents has been inventoried for all products, confirming more than 1 authorised agent per product
• □ All agency contracts have been cleared of exclusive import and exclusive distribution clauses
• □ The EDE licence type and scope of activities of each agent have been verified and records retained
• □ Annual minimum import obligations and the allocation of liability for shortfalls are set out in the contracts
• □ The commercial policy document unifies the ex-works price, rebates and cross-territory sales rules
• □ Document templates, traceability coding and the vigilance information return path have been standardised and issued to each agent
• □ A mechanism for certificate handover and stock buy-back upon agent change has been established
• □ Specific questions under the new mechanism have been submitted to EDE in writing and the replies retained

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the United Arab Emirates. Our team coordinates local authorised representative and importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com